Advanced therapies · United Kingdom
Gene therapy in the UK — real treatment, not just research.
Casgevy, Zolgensma, Luxturna, Roctavian, Hemgenix, Libmeldy and CAR-T are all NICE-approved and NHS-commissioned in 2026. Access is limited to a handful of specialist centres — we help you find the right pathway.
Why patients choose us
- 01
Real treatment, not a trial
Dozens of gene therapies are now NICE-approved and NHS-commissioned in the UK — Casgevy, Zolgensma, Luxturna, Roctavian, CAR-T and more. We help you find the pathway.
- 02
Rare-disease MDT access
Gene therapy is only delivered in a handful of specialist centres. We map the right MDT, the right consultant and the right commissioning route for your condition.
- 03
Independent, and free
We are not tied to any manufacturer, centre or clinic. The recommendation is impartial and the concierge is free to you.
UK-approved gene therapies
What is NICE-approved and NHS-commissioned in 2026.
List prices are what manufacturers charge — NHS access is via confidential commercial agreements and specialist commissioning. Patients do not pay out of pocket.
In short
Casgevy — the world’s first CRISPR therapy — is NHS-commissioned in the UK: NICE TA1011/1012, 2024.
| Therapy | Indicative cost | Delivery | Approval / route |
|---|---|---|---|
| Onasemnogene abeparvovec (Zolgensma) — SMA type 1 | £1.79M list (NHS) | Single IV infusion | NICE TA755 |
| Voretigene neparvovec (Luxturna) — RPE65 IRD | £613k per eye (NHS) | Subretinal | NICE TA633 |
| Casgevy — sickle cell / β-thalassaemia (CRISPR) | £1.65M list (NHS) | Ex-vivo, 6–9 mo | NICE TA1011/1012 |
| Roctavian — haemophilia A (AAV5) | £1.85M list (NHS) | Single IV infusion | NICE TA872 |
| Hemgenix — haemophilia B (AAV5) | £2.6M list (NHS) | Single IV infusion | NICE TA875 |
| CAR-T (Kymriah, Yescarta, Tecartus, Carvykti) | £280k–£450k (NHS) | Ex-vivo, 4–6 wk | Multiple NICE TAs |
| Libmeldy — metachromatic leukodystrophy | £2.87M list (NHS) | Ex-vivo lentiviral | Pre-symptomatic only |
| Concierge navigation and MDT introduction | Free | 1–2 working days | Same week |
List prices are for context — actual NHS spend is governed by confidential managed-access agreements negotiated by NHS England and the Cancer Drugs Fund. Access is decided by your specialist MDT against strict eligibility criteria.
The problem
The right diagnosis, the right product, the right centre.
Gene therapy is real — but access is narrow, information is fragmented, and pathways are opaque. We fix all three before you spend months waiting on the wrong route.
-
Diagnosis unclear?
We route you to Genomics England or an accredited panel before anything else — no confirmed genotype, no eligible therapy.
-
Product ambiguous?
Multiple products for one condition (SMA has Zolgensma and Spinraza). We compare NICE criteria and the evidence honestly.
-
Centre unknown?
Only a handful of NHS centres deliver each therapy. We map the closest accredited MDT and coordinate the referral.
The journey
From enquiry to lifetime follow-up — what happens, in order.
A rare-disease MDT leads clinically. We handle navigation, commissioning paperwork and the long-tail of registry follow-up.
Phase 1 · Before treatment
Diagnosis, referral, commissioning
Phase 2 · Delivery
Hospital admission and infusion
Phase 3 · After
Registry, decades
- 01
Before
You tell us the diagnosis
A short, confidential form. The condition, the genetic confirmation (Genomics England or private panel), age and prior treatments.
- 02
Before
We map the eligible therapy
Within one to two working days: which licensed product applies, whether NICE has issued a TA, and which UK specialist centre delivers it.
- 03
Before
Referral and commissioning
We coordinate the NHS England Highly Specialised Services referral, Cancer Drugs Fund route or individual funding request — with your consultant leading.
- 04
Delivery
Workup, apheresis or vector delivery
Ex-vivo therapies need cell collection and conditioning chemotherapy. In-vivo AAV therapies are given as a single infusion, subretinal injection or intrathecal dose.
- 05
Delivery
Inpatient recovery
A short hospital stay for monitoring — cytokine release, hepatic function, immune response, engraftment. Length varies by platform.
- 06
After
First-year intensive follow-up
Frequent bloods, imaging and disease-specific biomarkers. Immune monitoring and antibody surveillance where relevant.
- 07
After
Long-term registry follow-up
Five to fifteen years — sometimes lifetime — under a mandated registry. Durability, delayed toxicity and secondary malignancy surveillance.
Typical end-to-end: 3–6 months from referral to infusion. Registry follow-up: 5–15 years or lifetime.
When it helps
When gene therapy is the right step.
The indications with a licensed UK product in 2026, plus the one situation where the first step is genetic testing, not therapy.
-
Spinal muscular atrophy (SMA)
Type 1 in infants under 24 months — onasemnogene abeparvovec (Zolgensma). Nusinersen (Spinraza) for all types.
-
Sickle cell disease
Recurrent vaso-occlusive crises with failed hydroxycarbamide — Casgevy CRISPR gene editing, or Lyfgenia (assessment ongoing).
-
Transfusion-dependent β-thalassaemia
Regular transfusions and no matched sibling donor — Casgevy ex-vivo gene editing via NHS England.
-
Haemophilia A or B
Severe factor VIII or IX deficiency — Roctavian (AAV5) for A, Hemgenix (AAV5) for B. Single infusion, years of factor-free bleeding.
-
Inherited retinal dystrophy (RPE65)
Biallelic RPE65 mutations with viable retinal cells — voretigene neparvovec (Luxturna) subretinal AAV.
-
Metachromatic leukodystrophy (MLD)
Pre-symptomatic late-infantile or early-juvenile disease — Libmeldy autologous lentiviral gene therapy.
-
Haematological cancers (CAR-T)
Relapsed/refractory B-cell lymphomas, ALL, multiple myeloma — Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti.
-
Red flag: no genetic confirmation
Gene therapy needs a confirmed molecular diagnosis. If genetics are unclear, the first step is Genomics England panel testing — not a therapy referral.
Modalities
Gene therapy is not one thing — it is eight.
Different modalities suit different diseases. The delivery route, the vector serotype and whether the treatment is in-vivo or ex-vivo all shape eligibility and follow-up.
-
Ex-vivo autologous cell therapy
Your own cells collected by apheresis, modified in a lab, and reinfused after conditioning chemotherapy. CAR-T, Casgevy, Libmeldy, Strimvelis.
-
In-vivo AAV vector (systemic)
A single intravenous infusion of an adeno-associated virus carrying the therapeutic gene. Zolgensma, Roctavian, Hemgenix — often one dose for life.
-
In-vivo AAV vector (local)
Delivered directly to the target tissue — subretinal for Luxturna, intrathecal for CNS-directed therapies, intramuscular for some pipeline products.
-
CRISPR/Cas9 gene editing
Precise cutting and repair of a target gene. Currently ex-vivo (Casgevy for haemoglobinopathies) with in-vivo CRISPR emerging in trials.
-
Antisense oligonucleotide (ASO)
Repeated intrathecal or subcutaneous dosing to modulate RNA. Spinraza for SMA, Exondys for Duchenne, eplontersen for hATTR.
-
siRNA / RNAi therapies
Small interfering RNA silences a disease-causing gene. Patisiran and vutrisiran for hATTR amyloidosis, givosiran for AIP, lumasiran for PH1.
-
Lentiviral gene addition
Integrating vector used ex-vivo — Libmeldy for MLD, historical Strimvelis for ADA-SCID. Long-term integration requires lifetime monitoring.
-
Pipeline and clinical trials
Active UK trials in LHON, choroideraemia, USH1B, XLRP, achromatopsia and in-vivo CRISPR. We can point you to the relevant NIHR trial site.
Our vetted UK network
NHS commissioned centres, we know how to reach them.
A handful of centres in London, Manchester, Sheffield, Newcastle, Birmingham and Bristol deliver gene therapy in the UK. We map the closest accredited MDT for your product and coordinate the referral privately.
Selection criteria
How we choose every centre in our network.
-
NHS England commissioned gene therapy centres — not general private clinics
-
Consultant leadership by geneticist, haematologist, ophthalmologist or oncologist with product-specific accreditation
-
Genomics England confirmation or accredited private panel before referral
-
Long-term registry follow-up (5–15 years, sometimes lifetime) organised at the outset
Safety and monitoring
What to expect — honestly, and by platform.
Every gene therapy carries platform-specific risks and needs long-term surveillance. Nothing here is a substitute for the consent discussion at the treating centre — but you should walk in knowing the shape of it.
-
CAR-T: CRS and ICANS
Cytokine release syndrome and neurotoxicity (ICANS) are the two big early risks. Managed with tocilizumab, steroids, ICU support in specialist centres.
-
AAV: hepatotoxicity
High-dose IV AAV (Zolgensma, Roctavian, Hemgenix) can trigger transient liver enzyme rises. Steroid cover and weekly LFTs for months are standard.
-
AAV: neutralising antibodies
Once dosed, most patients develop antibodies to the vector — redosing is usually not possible. Pre-treatment antibody screening decides eligibility.
-
Ex-vivo: myeloablative conditioning
Casgevy, Libmeldy and CAR-T (for ALL) need chemotherapy before infusion. Risks include infection, cytopenias, infertility and, rarely, GvHD-like effects.
-
Secondary malignancy — FDA warning 2024
The FDA issued a class warning for CAR-T secondary T-cell malignancies. Rare but real; part of the lifelong monitoring.
-
CRISPR: off-target editing
Theoretical off-target edits are extensively screened pre-approval. Real-world durability data for Casgevy is early but strong so far.
-
Variable and incomplete response
Not every patient responds fully. Zolgensma works best under six months; Luxturna needs viable RPE cells; CAR-T remission rates vary by indication.
-
Cost and access
Products list at £500k–£3M. NHS access is via NICE TA plus specialist commissioning — not self-pay in the UK for most indications.
-
Red flags
Fever, breathlessness, confusion, unexplained bleeding or new jaundice after gene therapy — contact the treating centre immediately, not your GP.
Reading your treatment summary
Your gene therapy summary in four parts. Read the last one first.
Whichever product was used, the summary the centre sends you keeps to the same shape.
A quiet reminder
Molecular and vector language is dense — we translate it for you.
If you would like us to talk you through the summary before your review, just ask.
- 01 Header
Diagnosis, genotype and product used
The condition, the confirmed genotype (and where tested — Genomics England or private lab), and the licensed product administered.
- 02 Technique
Dose, vector and delivery route
The vector serotype (AAV5, AAV9, lentivirus, etc), dose in vg/kg or cells/kg, delivery route, and any pre-conditioning chemotherapy.
- 03 Findings
Response, biomarkers and antibodies
Disease-specific biomarkers (factor VIII levels, HbF percentage, motor milestones, visual acuity), vector shedding, and immune response.
- 04 Impression
Follow-up schedule and registry
Read this first: the mandated long-term registry (5–15 years or lifetime), red-flag symptoms, and who to contact for what.
Recognised by major UK insurers
UK gene therapy is delivered under NHS England Highly Specialised Services, the Cancer Drugs Fund and NICE-approved managed access. Private insurance rarely funds ATMP products directly — we clarify the route before referral.
Frequently asked
Everything we get asked about gene therapy in the UK.
Straight answers on approved products, NHS access, CRISPR, in-vivo vs ex-vivo, risks and long-term follow-up.
-
Is gene therapy actually available on the NHS in 2026?
Yes — dozens of NICE-approved gene therapies are commissioned by NHS England, including Casgevy (CRISPR for sickle cell and β-thalassaemia), Zolgensma (SMA), Luxturna (RPE65 retinal dystrophy), Roctavian (haemophilia A), Hemgenix (haemophilia B) and multiple CAR-T products. Access is via specialist centres and Highly Specialised Services commissioning.
-
Can I pay for gene therapy privately in the UK?
For most licensed products, no. List prices run £500k–£3M and delivery is restricted to a small number of accredited NHS centres. A handful of CAR-T products can be arranged privately for select oncology cases. We tell you honestly which route applies to your condition.
-
What is Casgevy and how does CRISPR gene editing work?
Casgevy (exagamglogene autotemcel) is the world’s first approved CRISPR gene-editing therapy. Your bone marrow stem cells are collected, edited to reactivate fetal haemoglobin, and reinfused after conditioning chemotherapy. NICE approved it in 2024 for sickle cell disease (TA1011) and transfusion-dependent β-thalassaemia (TA1012).
-
How is Zolgensma different from Spinraza?
Zolgensma is a one-time AAV9 gene therapy that delivers a working SMN1 gene — for SMA type 1 infants under 24 months (NICE TA755). Spinraza (nusinersen) is an antisense oligonucleotide given intrathecally every four months, approved for all SMA types (NICE TA588). They are different modalities with different pathways.
-
What is the difference between in-vivo and ex-vivo gene therapy?
In-vivo therapies are delivered directly into your body — usually as a single IV infusion, subretinal injection or intrathecal dose using an AAV vector. Ex-vivo therapies collect your cells (or donor cells), modify them in a lab, and reinfuse them after conditioning chemotherapy. CAR-T, Casgevy, Libmeldy and Strimvelis are ex-vivo; Zolgensma, Luxturna, Roctavian and Hemgenix are in-vivo.
-
What are the main risks of gene therapy?
They are platform-specific. CAR-T carries cytokine release syndrome, neurotoxicity and a class warning for secondary T-cell malignancies. AAV therapies can cause transient hepatotoxicity and generate neutralising antibodies that prevent redosing. Ex-vivo therapies involve conditioning chemotherapy with infection, cytopenia and infertility risks. Long-term durability data is still accumulating for most products.
-
How long does follow-up last after gene therapy?
Between five and fifteen years for most products, and lifetime for lentiviral and CRISPR platforms — under a mandated registry. Follow-up covers durability of response, delayed toxicity, immune surveillance and, for integrating vectors, monitoring for secondary malignancy.
-
What is Genomics England and why does it matter?
Genomics England runs the NHS Genomic Medicine Service, offering whole-genome and panel testing for rare-disease and cancer patients. A confirmed molecular diagnosis is a prerequisite for almost every gene therapy referral — so the first step, if genetics are unclear, is testing not therapy.
-
How do I get referred for gene therapy in the UK?
Through a rare-disease MDT or specialist consultant — paediatric neurology for SMA, haematology for sickle cell/thalassaemia/haemophilia, ophthalmology for RPE65, or oncology for CAR-T. NHS England commissioning is via Highly Specialised Services, the Cancer Drugs Fund or an individual funding request. We map the right route for your case.
Related tests